Researchers at Northern Arizona University (NAU) are pioneering a groundbreaking diagnostic strategy that promises to significantly enhance the early identification of Alzheimer’s disease, potentially enabling interventions that could decelerate its advancement. This innovative approach centers on the intricate metabolic processes within the brain, specifically examining how it utilizes glucose, the primary energy source essential for cognitive functions, motor control, and emotional regulation.
At the forefront of this endeavor is Travis Gibbons, an assistant professor within NAU’s Department of Biological Sciences. His work, bolstered by crucial funding from the Arizona Alzheimer’s Association, delves into the fundamental energetic requirements of the brain. Gibbons likens the brain to a highly active muscle, explaining, "The brain is like a muscle. It needs fuel to do work, and its gasoline is blood glucose. A healthy brain is greedy; it burns through glucose fast. But brain metabolism is slower when you have Alzheimer’s. It can be viewed as a canary in the coal mine in the development of the disease." This analogy underscores the critical role of glucose metabolism as an early indicator of neurological compromise.
Historically, the direct measurement of brain glucose metabolism has posed considerable challenges due to the organ’s protected and inaccessible location. Previous research methodologies often involved highly invasive procedures, such as the insertion of catheters into neck veins to obtain blood samples directly from the brain’s venous outflow. Such interventions are clearly impractical and incompatible with routine clinical assessments, thus limiting the feasibility of early and widespread diagnostic screening.
The NAU team, led by Gibbons, is currently exploring a far less intrusive alternative. Their focus is on utilizing commercially available assay kits designed for the isolation and analysis of circulating microvesicles found within the bloodstream. Microvesicles are tiny, membrane-bound sacs released by cells, acting as cellular messengers that carry a variety of biomolecules, including proteins and genetic material. Gibbons elaborates on their significance: "Some of these microvesicles originate in a neuron in your brain, and they’re like messengers carrying cargo. With these test kits, we can find what kind of cargo is in a microvesicle and run tests on it. It’s been described as a biopsy for the brain, but much less invasive. That’s the appeal of it." This concept of a non-invasive "biopsy for the brain" represents a paradigm shift in diagnostic possibilities.
While this microvesicle-based methodology is still in its developmental stages, it holds the potential to fundamentally transform the landscape of Alzheimer’s detection and ongoing patient monitoring. Gibbons acknowledges the demanding nature of the protocol, emphasizing the need for meticulous technique and considerable patience, but also highlights the profound potential benefits. "The workflow is demanding and requires careful technique and patience, yet the possible payoff is significant," he notes.
Building upon prior research, Gibbons and his collaborators previously investigated the effects of intranasal insulin delivery, a method shown to facilitate more efficient brain access compared to traditional systemic administration. Following this, the research team successfully identified specific biomarkers within blood collected from the brain’s venous drainage, which were associated with enhanced neuroplasticity. The current objective is to detect these identical or similar biomarkers within the microvesicles isolated from peripheral blood. This strategy aims to bridge the gap between direct brain sampling and a more accessible peripheral blood test.
The research is progressing through a carefully structured, phased approach. Initially, Gibbons is focused on validating the efficacy and reliability of the microvesicle analysis technique in healthy individuals, establishing a baseline for normal metabolic profiles. The subsequent phase will involve comparing these findings with data obtained from individuals diagnosed with mild cognitive impairment and those with a confirmed Alzheimer’s diagnosis. The ultimate goal is to ascertain whether discernible alterations in brain glucose metabolism, as reflected in microvesicle cargo, can serve as reliable indicators of disease progression.
Gibbons articulates a broader vision for the future of neurological health management: "Brain function is notoriously hard to measure, but we’re getting better and better at interrogating brain function through biomarkers. Soon, we might be able to help people protect their brain health and prevent Alzheimer’s disease the same way we protect people from cardiovascular disease by prescribing moderate exercise and a healthy diet. That will help us manage the burden on aging people and society as a whole." This perspective emphasizes a proactive, preventative model for brain health, drawing parallels with established strategies for managing cardiovascular conditions. The potential to identify and address Alzheimer’s risk factors before the onset of debilitating symptoms could revolutionize elder care and significantly alleviate the societal and economic impact of this devastating disease.
This crucial research is being conducted under the umbrella of the Arizona Alzheimer’s Consortium (AAC), a collaborative network dedicated to advancing Alzheimer’s research and care. Gibbons is working alongside fellow AAC member Emily Cope, an associate professor of biological sciences at NAU, and K. Riley Connor, a Ph.D. student in biological sciences at NAU. The project also benefits from the expertise of Philip Ainslie, a distinguished professor at the University of British Columbia’s Centre for Heart, Lung & Vascular Health, bringing a multidisciplinary perspective to this vital investigation. The collaborative nature of this research underscores the complexity of Alzheimer’s disease and the necessity of diverse scientific input to unravel its mysteries and develop effective solutions.
About the Author
